Loading patent…
AssigneeNational Cancer Center
InventorsSoo Youl Kim, Sang Myung Woo, Woo Jin Lee, Tae Hyun Kim, Sang Jae Park, Ju Hee Lee, Sung Sik Han, Eun Kyung Hong
Estimating the term…
The present disclosure relates to a pharmaceutical composition comprising a combination of anticancer agents, capable of creating a synergistic effect when co-administer in the treatment of cancer, and more specifically, the present invention suggests anticancer agents capable of creating a synergistic effect when co-administered with gossypol and phenformin. The anticancer agents selected as said anticancer agents in the present disclosure are sorafenib, vemurafenib, irinotecan, cisplatin, paclitaxel, and doxorubicin, and each of the aforementioned anticancer agent, when co-administered as a triple-drug combination with gossypol and phenformin can provide a significant synergistic effect in terms of the effect of suppressing the proliferation of cancer and killing cancer cell, compared to each mono-drug treatment group and a dual-drug treatment group of gossypol+phenformin.
A method for treating pancreatic cancer, comprising administering to a patient in need thereof a pharmaceutical composition which comprises gossypol, phenformin, and an anticancer agent, or pharmaceutically acceptable salts thereof, as active ingredients, wherein the anticancer agent is at least one selected from the group consisting of irinotecan, gemcitabine, and paclitaxel, wherein the pharmaceutical composition comprises the gossypol, the phenformin, and the anti-cancer agent in the form of being mixed in a molar ratio of 0.1to 10:10 to 500:1.
Dependencies are inferred from the claim text.